Omega Fund Management, LLC
13F Reported Value
ⓘ$163.1M
Holdings
10
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Omega Fund Management, LLC disclosed 10 positions worth $163.1M in its Form 13F-HR for Q1 2026, led by $BCAX (Bicara Therapeutics Inc.) at 29.2% of the equity portfolio, followed by $NUVB and $BBOT. During the quarter the fund opened 0 new positions and exited 1 and a full exit from $UPB. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Omega Fund Management, LLC’s Form 13F-HR filing with the SEC under CIK 1637359.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$47.6M2,392,150 sh - 29.5#2,400
Quality
$34.7M8,081,089 sh - $29.4M3,289,661 sh
- 30.8
Quality
$20.4M1,022,149 sh - 22.8
Quality
$13.2M1,316,183 sh - —
Quality
$6.0M876,357 sh - 9.2
Quality
$5.3M241,255 sh - —
Quality
$2.4M843,750 sh - 3.9
Quality
$2.3M455,361 sh - —
Quality
$1.9M248,672 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Bicara Therapeutics Inc.$BCAX | — | $47.6M | 2,392,150 |
 Nuvation Bio Inc.$NUVB | 29.5#2,400 | $34.7M | 8,081,089 |
 BridgeBio Oncology Therapeutics, Inc.$BBOT | — | $29.4M | 3,289,661 |
 KESTRA MEDICAL TECHNOLOGIES, LTD.$KMTS | 30.8 | $20.4M | 1,022,149 |
 Beta Bionics, Inc.$BBNX | 22.8 | $13.2M | 1,316,183 |
 enGene Therapeutics Inc.$ENGN | — | $6.0M | 876,357 |
 ALUMIS INC.$ALMS | 9.2 | $5.3M | 241,255 |
 Sana Biotechnology, Inc.$SANA | — | $2.4M | 843,750 |
 ImageneBio, Inc.$IMA | 3.9 | $2.3M | 455,361 |
 Replimune Group, Inc.$REPL | — | $1.9M | 248,672 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Omega Fund Management, LLC's 10 positions.
Showing top 10 of 10 holdings.
Sector Allocation
Healthcare
$163.1M
Full Holdings — Omega Fund Management, LLC (Q1 2026)
All 10 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $BCAX | Bicara Therapeutics Inc. | $47.6M | 29.2% | +9% | — |
| 2 | $NUVB | Nuvation Bio Inc. | $34.7M | 21.3% | +0% | 29.5 |
| 3 | $BBOT | BridgeBio Oncology Therapeutics, Inc. | $29.4M | 18.1% | +0% | — |
| 4 | $KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | $20.4M | 12.5% | -26% | 30.8 |
| 5 | $BBNX | Beta Bionics, Inc. | $13.2M | 8.1% | +0% | 22.8 |
| 6 | $ENGN | enGene Therapeutics Inc. | $6.0M | 3.7% | +0% | — |
| 7 | $ALMS | ALUMIS INC. | $5.3M | 3.3% | -63% | 9.2 |
| 8 | $SANA | Sana Biotechnology, Inc. | $2.4M | 1.5% | +0% | — |
| 9 | $IMA | ImageneBio, Inc. | $2.3M | 1.4% | +0% | 3.9 |
| 10 | $REPL | Replimune Group, Inc. | $1.9M | 1.2% | +0% | — |
Exited Positions (1)
$UPB Upstream Bio, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Omega Fund Management, LLC including:
Track Omega Fund Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Omega Fund Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Omega Fund Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Omega Fund Management, LLC (SEC CIK: 1637359), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Omega Fund Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.